Lopinavir-Ritonavir plus either Raltegravir or 2-3 NRTIs
SELECT Trial
Lopinavir-Ritonavir plus either Raltegravir or 2-3 NRTIs

SELECT: Study Design

Study Design: SELECT

• **Background**: Randomized, phase 3, open-label trial to compare dual therapy with lopinavir-ritonavir plus raltegravir with WHO 2nd line standard-of-care regimen of lopinavir-ritonavir plus NRTIs

• **Inclusion Criteria** (n=412)
  - Age ≥ 18
  - On initial ART containing NNRTI for ≥ 24 weeks
  - No virologic failure
  - Naïve to protease inhibitors
  - No known broad NRTI resistance

• **Treatment Arms***
  - Lopinavir-ritonavir + Raltegravir
  - Lopinavir-ritonavir + 2 or 3 NRTIs

*L95% in RAL group and 97% in NRTI group had at least 1 NRTI RAM at baseline

Lopinavir-Ritonavir plus either Raltegravir or 2-3 NRTIs

SELECT: Results

Week 48: Virologic Response (Missing Data Ignored)

Lopinavir-Ritonavir plus either Raltegravir or 2-3 NRTIs

SELECT: Results

Virologic Failure and Adverse Events

### HIV Resistance Testing at Virologic Failure

<table>
<thead>
<tr>
<th></th>
<th>LPV-RTV + RAL (n = 258)</th>
<th>LPV-RTV + NRTIs (n = 254)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with virologic failure, n (%)</td>
<td>46 (18%)</td>
<td>50 (20%)</td>
</tr>
<tr>
<td>Any mutation at virologic failure</td>
<td>85%</td>
<td>90%</td>
</tr>
<tr>
<td>New resistance mutations at virologic failure</td>
<td>26%</td>
<td>29%</td>
</tr>
</tbody>
</table>

Interpretation: “In settings with extensive NRTI resistance but no available resistance testing, our data support WHO's recommendation for ritonavir-boosted lopinavir plus NRTI for second-line antiretroviral therapy. Ritonavir-boosted lopinavir plus raltegravir is an appropriate alternative, especially if NRTI use is limited by toxicity.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.